Halozyme Therapeutics (HALO) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Halozyme Therapeutics (HALO) over the last 14 years, with Q4 2025 value amounting to $43.89.
- Halozyme Therapeutics' Debt to Equity rose 96053.21% to $43.89 in Q4 2025 from the same period last year, while for Dec 2025 it was $43.89, marking a year-over-year increase of 96053.21%. This contributed to the annual value of $43.89 for FY2025, which is 96053.21% up from last year.
- According to the latest figures from Q4 2025, Halozyme Therapeutics' Debt to Equity is $43.89, which was up 96053.21% from $3.0 recorded in Q3 2025.
- Halozyme Therapeutics' 5-year Debt to Equity high stood at $43.89 for Q4 2025, and its period low was $0.32 during Q3 2021.
- Its 5-year average for Debt to Equity is $8.2, with a median of $4.49 in 2025.
- In the last 5 years, Halozyme Therapeutics' Debt to Equity surged by 649568.38% in 2023 and then crashed by 7686.39% in 2024.
- Halozyme Therapeutics' Debt to Equity (Quarter) stood at $4.45 in 2021, then surged by 99.27% to $8.87 in 2022, then surged by 101.68% to $17.89 in 2023, then tumbled by 76.86% to $4.14 in 2024, then soared by 960.53% to $43.89 in 2025.
- Its Debt to Equity stands at $43.89 for Q4 2025, versus $3.0 for Q3 2025 and $4.54 for Q2 2025.